Insights from BCC Research

Among Other Apps, Smart Pills Could Help Staunch the Opioid Epidemic

Posted by Laurie L. Sullivan on Feb 7, 2018 11:30:00 AM

Pill_Bottle.jpgThe opioid epidemic continues as one of America’s greatest public health crises as healthcare officials, public officials and countless Americans struggle to prevent opioid abuse, addiction and death. In a blog from 2017, Laurie Sullivan explores how one solution, known as The Smart Pill Drug Delivery Device, could be used to curb the crisis. Another possible solution? Prescribing more non-opioid painkillers. Click here to be notified when the BCC Research report “Non-opioid Pain Treatment: Global Markets to 2022” publishes later this month.

Smart pills are increasingly influencing our health. They are noninvasive and have redefined diagnosis, disease monitoring, and treatment adherence. By 2021, US sales of smart pills may double, reaching $1.2 billion. The global market for smart pills is poised to exceed a 20% compound annual growth rate (CAGR) during the next five years, according to BCC Research’s recent study, Smart Pills: Applications and Global Markets. High-growth application areas include capsule endoscopy, patient monitoring, and delivery of therapeutic agents. The adoption of advanced ingestible medical sensor technologies is a key growth driver.

Read More

Topics: Life Sciences, Pharmaceuticals

FDA Approves First Digital Pill in Growing Medication Adherence Market

Posted by Laurie L. Sullivan on Dec 11, 2017 11:00:00 AM

First Digital Pill.jpegA higher incidence of chronic diseases worldwide and the demand for advanced medication adherence systems are fueling growth in this market, which has the potential to surpass $3.9 billion by 2021. A new study by BCC Research examines the industry’s prospects and technologies by disease applications and geographical regions.

Read More

Topics: Life Sciences, Pharmaceuticals

Liquid Biopsy Market Soars Ever Higher

Posted by Laurie L. Sullivan on Oct 9, 2017 11:00:00 AM

Liquid biopsy is rapidly gaining traction as a supplement or alternative to tissue biopsy. Earlier this year, we noted that liquid biopsies continue to draw investments, and efforts prevail to establish the technique in mainstream medicine. Liquid biopsies have been likened to a Holy Grail of cancer treatment. By means of a simple blood draw, liquid biopsies aim to replace needle biopsies of solid tumors, which can be expensive for the healthcare system as well as painful for patients. For diagnosis of cancer, liquid biopsies could spare some of the risky tissue biopsies and reduce reliance on computed tomography scans, which must be limited because of the danger posed by overexposure to radiation.

Read More

Topics: Life Sciences, Pharmaceuticals

As Demand Surges, Drug Tests Deliver on Speed and Simplicity

Posted by Laurie L. Sullivan on Sep 13, 2017 11:00:00 AM

fingerprint-Drug Testing.jpgThe steadily increasing demand for substance abuse test equipment forms a building block for medical technology companies, according to a new study by BCC Research. From estimated sales of $3 billion in 2016, the global drug testing industry is predicted to reach almost $4 billion by 2022. Technological advances and the entry of new innovative companies in the diagnostics industry have transformed the market.

Read More

Topics: Life Sciences, Pharmaceuticals